Navigation Links
Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
Date:8/27/2007

antigen in autoimmune diabetes, is the active substance in Diamyd. GAD65 is also an enzyme that converts the excitatory neurotransmitter glutamate to the inhibitory transmitter GABA. In this context, GAD may have an important role not only in diabetes but also in several central nervous system-related diseases. Diamyd Medical has an exclusive worldwide license from the University of California at Los Angeles regarding the therapeutic use of the GAD65 gene.

Diamyd Medical has sublicensed its UCLA GAD Composition of Matter license to Neurologix, Inc. in Fort Lee, New Jersey for treatment of Parkinson's disease with an AAV-vector.

Other projects comprise drug development within therapeutic gene transfer using the exclusively licensed and patent protected Nerve Targeted Drug Delivery System (NTDDS). The company's lead NTDDS projects include using enkephalin and GAD for chronic pain, e.g., diabetes pain or cancer pain. All projects in this field are currently in preclinical phases.

Diamyd Medical has offices in Stockholm, Sweden and Pittsburgh, PA. The Diamyd Medical share is quoted on the Stockholm Nordic Exchange in Sweden (NOMX ticker: DIAM B) and on the OTCQX-list in the United States (ticker: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further information is available at http://www.diamyd.com.

For further information, please contact:

Stockholm office

Anders Essen-Moller

CEO and President +46 8 661 0026

investor.relations@diamyd.com

Pittsburgh office

Michael Christini

President

+1 412 770 1310

Michael.Christini@diamyd.com

For media contact in the US, please contact:

Gregory Tiberend, Executive Vice President

Richard Lewis Communications, Inc.

+1 212 827 0020

E-mail:

SOURCE Diamyd Medical AB
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Revolutionary Immunologic Data Explains Function of Diamyd Diabetes Vaccine
2. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
3. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
4. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
5. NCCN Updates Esophageal and Gastric Cancer Guidelines
6. Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
7. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
8. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
9. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
10. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
11. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... December 17, 2014 , ... than a hub of information concerning the biopharmaceutical Group,s national ... A further addition to the recently launched institutional website that ... now been enriched by a new chapter in the fascinating ... A richly detailed and panoramic hub on the world of ...
(Date:12/17/2014)... , Dec. 17, 2014  RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today announced completion of enrollment in its first ... the 3-month observations confirmed the 1-month findings that ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/15/2014)... LONDON , December 15, 2014 /PRNewswire/ ... Am 19. und 20. Februar ... das Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ... zu besuchen. Diese Tagung ... Gemeinschaft die Möglichkeit geben, die neue profitablen ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... Fla., March 29, 2011 SinoFresh® HealthCare, Inc., (Pink ... has signed contracts with three high volume sales agencies. ... significant boost to long term sales and distribution along ... make SinoFresh,s Antiseptic Homeopathic Nasal and Sinus Care Spray ...
... PARSIPPANY, N.J. and INDIANAPOLIS, March 29, 2011 ... to the updated clinical practice guidelines as a ... percutaneous coronary intervention (PCI) after experiencing heart-related chest ... elevation myocardial infarction (NSTEMI).  NSTEMI is a type ...
Cached Medicine Technology:SinoFresh HealthCare Signs Three Sale Marketing Agreements 2SinoFresh HealthCare Signs Three Sale Marketing Agreements 3Effient® Added to Updated ACCF/AHA Clinical Guidelines for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial Infarction 2Effient® Added to Updated ACCF/AHA Clinical Guidelines for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial Infarction 3Effient® Added to Updated ACCF/AHA Clinical Guidelines for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial Infarction 4Effient® Added to Updated ACCF/AHA Clinical Guidelines for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial Infarction 5Effient® Added to Updated ACCF/AHA Clinical Guidelines for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial Infarction 6
(Date:12/19/2014)... 2014 If you have ever been ... you probably wished you had an arsenal of treatments ... fibrosis, and other breathing disorders. Currently, the only proven ... triggers, but other common treatments do exist. At ... San Antonio, TX, 34 asthma educators responded to a ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 This is ... of the global Gliquidone industry with a focus on ... the market status of the Gliquidone manufacturers and is ... and individuals interested in the industry. , Firstly, the ... its definition, applications and manufacturing technology. Then, the report ...
(Date:12/19/2014)... 2014 (HealthDay News) -- A new study suggests a ... severe hot flashes and night sweats -- and higher ... flashes are common during menopause, affecting about 60 percent ... women after menopause, since they then face a higher ... suggest women who exhibit moderate or severe menopausal symptoms ...
(Date:12/19/2014)... Traveling through the same U.S. airport gate, one infected ... a four-hour time span, illustrating just how easily the ... exposures in this report were not prolonged and occurred ... the fact that measles is highly contagious," wrote a ... at the U.S. Centers for Disease Control and Prevention. ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Dr. Myo Nwe ... Weight Loss Diet of the Future” and co-founder of the ... her book, Dr. Nwe takes a broad look at the ... hold up under scientific scrutiny. On film and in television ... emphasized mostly toward the social aspects and played for basic ...
Breaking Medicine News(10 mins):Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 2Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2
... at Capitol to meet with legislators LANSING, Mich., May ... childhood investment supporters are expected at the Capitol Thursday, ... our youngest citizens is critical to Michigan,s economic future.It ... began in 2007."This issue is more important than ever ...
... announced today that it is making a $10,000 donation ... in the Santa Barbara area who have been impacted by ... In addition, Anthem announced today several additional actions it is ... Anthem Blue Cross members may have left ...
... May 8 Bertalan Mesko, medical blogger and health ... collections featuring medical and scientific videos and animations. ... from the best quality. Some of the sites are ... reliable videos focusing on health issues, while others were ...
... more likely to experience complications, study finds , , FRIDAY, ... likely than any other racial group to suffer serious ... procedures, but the reasons for these worse outcomes aren,t ... included 1,410 patients, average age 57, who had a ...
... May 8 The majority of uninsured American families ... an employer cannot afford to buy health insurance, according ... Research and Quality.Some experts have suggested that because 23.8 ... have access to employer-based health insurance have incomes above ...
... Free Student Memberships Now Available on Online Community ... Medical Device TechnologiesFERNANDINA BEACH, Fla., May 8 ... just a few short weeks since launch, e-Zassi.com ... medical device industry participants involved in the discovery, ...
Cached Medicine News:Health News:Early Childhood Funding is Focus of Star Power Event 2Health News:Anthem Blue Cross to Support Members and Communities Impacted by Santa Barbara Fires 2Health News:Racial Disparity Seen in Angioplasty Outcomes 2Health News:New Study Finds Fewer Families Can Afford Health Insurance 2Health News:New Advanced Search and Matching Function Drives e-Zassi.com's Enhanced Functionality 2
... Focus from Thermo Labsystems was designed specifically ... Advanced features such as the new fast ... on microvolumes help to define this as ... The new interchangeable handle plate offers a ...
... range from 2ul to 5000ul. Fills and ... prevents inadvertent volume change. Novel hand grip ... is autoclavable at 121C(250F). To prevent corrosion ... for one-handed operation. Auto or Normal trigger ...
... Reference Series 2000 Pipette is a synonym ... compact and robust design, and superior operating ... to operate the measuring stroke and blow-out ... Product features: Eppendorf "pipette/tip" system ensures ...
This adjustable-volume digital micropipet is used to accurately measure and transfer small solution volumes in the 0.5-10 microliter range....
Medicine Products: